Study to Determine the Effect of a Newly Formulated Tetracaine Product PET500 on Penile Skin Sensation

Overview

An open label, placebo and positive controlled, randomised, cross-over study in healthy male volunteers to determine the effect on penile skin sensation of a newly formulated tetracaine product PET500

Full Title of Study: “An Open Label, Placebo and Positive Controlled, Randomised, Cross-over Study in Healthy Male Volunteers to Determine the Effect on Penile Skin Sensation of a Newly Formulated Tetracaine Product PET500”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 20, 2008

Detailed Description

This was an open label, placebo and positive controlled, randomised, dose-ranging, cross-over pilot study. On each dosing day the subjects each received one dose of tetracaine (0.26 or 0.65 or 1.3mg), or placebo, or Stud100® (which served as a positive control) on the glans penis The doses of PET500 were applied in liquid spray form (260μl) at approximately the same time of the day as the previous application to locations on the glans penis in a randomised fashion. Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP. The first two volunteers included in the trial piloted the sensitivity assessments prior to the inclusion of all other subjects. Changes could be made to the assessment times on the basis of the pilot data to ensure subsequent timings were relevant. However any such changes were not to expose volunteers to more assessments than were specified in the study protocol.

Interventions

  • Drug: Tetracaine
    • Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
  • Other: Matching placebo (PET500)
    • Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
  • Drug: STUD100
    • Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.

Arms, Groups and Cohorts

  • Experimental: PET500 (0.1%)
    • Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows: PET500 (0.1%) corresponding to a tetracaine total dose of 0.26mg
  • Experimental: PET500 (0.25%)
    • Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows: PET500 (0.25%) corresponding to a tetracaine total dose of 0.65mg
  • Experimental: PET500 (0.5%)
    • Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows: PET500 (0.5%) corresponding to a tetracaine total dose of 1.3mg
  • Experimental: PET500 placebo comparator
    • Each actuation of the pump spray dispenses 130µl PET500 [vehicle only]. Two pumps will dispense 260µl
  • Active Comparator: STUD100 (9.6%)
    • Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of 23mg lidocaine. UK License Number PL/2294/5000R

Clinical Trial Outcome Measures

Primary Measures

  • Onset of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis assessed using Von Frey fibres (monofilaments) to measure touch sensitivity
    • Time Frame: 2 Months
    • To determine the onset of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis (compared to placebo and positive prilocaine/lidocaine control).
  • Duration of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis using Von Frey fibres (monofilaments) to measure touch sensitivity
    • Time Frame: 2 Months
    • To determine the duration of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis (compared to placebo and positive prilocaine/lidocaine control).

Secondary Measures

  • Incidence of adverse events for PET500
    • Time Frame: 2 months
    • To determine incidence, of adverse events by Treatment group for doses of a newly formulated tetracaine spray PET500 in healthy male volunteers.
  • Intensity and relationship of adverse events to PET500
    • Time Frame: 2 months
    • To determine intensity and relationship to study drug of adverse events by Treatment group for doses of a newly formulated tetracaine spray PET500 in healthy male volunteers.

Participating in This Clinical Trial

Inclusion Criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply: 1. Male healthy subject aged 18 to 65 years, inclusive. 2. The subject is capable of understanding and complying with protocol requirements. 3. The subject is in good health as determined by medical history and physical examination at screening. 4. The subject signs a written, informed consent form prior to the initiation of any study procedures Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply: 1 History or hypersensitivity to tetracaine or ethanol. 2. History or signs of a sexually transmitted disease. 3. Any current penile abnormalities. 4. Known current drug abuser or alcoholic as determined by medical history. 5. Participation in a clinical trial within the last month prior to dosing on Day 1. 6. The use of concomitant systemic or topical medications or foods that may affect the study outcome and / or impair drug metabolising capacity. 7. A positive HIV 1 & 2 antibodies, Hepatitis B surface antigen, and/or Hepatitis C antibody result. 8. Unfit to participate in the study in the opinion of the Principal Investigator.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Futura Medical Developments Ltd.
  • Collaborator
    • Richmond Pharmacology Limited
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jorg Taubel, Dr, Principal Investigator, Richmond Pharmacology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.